The British journal of ophthalmology · 2025
Prevalence and incidence of juvenile idiopathic arthritis-associated uveitis and medication trends in the TriNetX database.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Marshall Rayna, Thorne Jennifer, Berkenstock Meghan K
Аннотация
AIMS: To investigate the prevalence and incidence of juvenile idiopathic arthritis (JIA)-associated uveitis (JIA-U) in the USA from 2013 to 2023 by analysing the TriNetX database. Secondary outcomes analysed included disease demographics, associated ocular complications and immunosuppressive prescription trends.
METHODS: Patients with JIA-U were identified in the TriNetX database, a large, multicentre research network, through International Classification of Diseases, 10th Edition codes. Data collected included patient demographics, concurrent uveitic ocular complications, incidence, prevalence and cumulative prevalence of JIA-U in the 11-year period and immunosuppressive utilisation in the JIA population.
RESULTS: 4510 patients with JIA-U were included in this study. The cumulative prevalence and incidence of JIA-U over the 11-year period were 4.4 and 1.2 per 100 000 cases, both of which decreased over the study period. 5.5% of patients with JIA had a diagnosis of uveitis and 36.1% of patients with JIA-U had an associated uveitic ocular adverse event, including glaucoma, band keratopathy, low vision and blindness. The prevalence of immunosuppressive drug therapy in patients with JIA increased over the years 2013-2023.
CONCLUSION: In this large US database, the JIA-U prevalence and incidence rates decreased between 2013 and 2023. This may be partially attributed to the increasing prevalence of immunosuppressive drug use in patients with JIA.
METHODS: Patients with JIA-U were identified in the TriNetX database, a large, multicentre research network, through International Classification of Diseases, 10th Edition codes. Data collected included patient demographics, concurrent uveitic ocular complications, incidence, prevalence and cumulative prevalence of JIA-U in the 11-year period and immunosuppressive utilisation in the JIA population.
RESULTS: 4510 patients with JIA-U were included in this study. The cumulative prevalence and incidence of JIA-U over the 11-year period were 4.4 and 1.2 per 100 000 cases, both of which decreased over the study period. 5.5% of patients with JIA had a diagnosis of uveitis and 36.1% of patients with JIA-U had an associated uveitic ocular adverse event, including glaucoma, band keratopathy, low vision and blindness. The prevalence of immunosuppressive drug therapy in patients with JIA increased over the years 2013-2023.
CONCLUSION: In this large US database, the JIA-U prevalence and incidence rates decreased between 2013 and 2023. This may be partially attributed to the increasing prevalence of immunosuppressive drug use in patients with JIA.